



5 February 2021

(21-0935)

Page: 1/4

Committee on Market Access

Original: English

**NOTIFICATION PURSUANT TO THE DECISION ON NOTIFICATION PROCEDURES  
FOR QUANTITATIVE RESTRICTIONS (G/L/59/REV.1)**

EUROPEAN UNION

*Addendum*

The following communication, dated 4 February 2021, is being circulated at the request of the delegation of the European Union.

<b>A. Notifying Member:</b> European Union
<b>B. Date of notification:</b> 4 February 2021
<b>C. First time notification:</b> <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No, last notification was made in (doc. symbol): G/MA/QR/N/EU/5
<b>D. Type of notification:</b> <input type="checkbox"/> 1. Complete (i.e. notification of all quantitative restrictions in force) <input checked="" type="checkbox"/> 2. Changes to a notification previously made in (doc symbol) which are of the following nature: <input checked="" type="checkbox"/> 2.1 Introduction of new restrictions, as listed in Section 1. <input type="checkbox"/> 2.2 Elimination of restrictions, as described in G below. <input type="checkbox"/> 2.3 Modification of a previously notified restriction, as described in Section 1. <input type="checkbox"/> 3. Reverse notification of restrictions maintained by (Member):
<b>E. The notification provides information for the following biennial period (e.g. 2012-2014):</b> <u>2020-2022</u> <b>and relates to restrictions in force as of</b> 30.01.2021
<b>F. This notification contains information* relating to:</b> <input checked="" type="checkbox"/> <b>Section 1:</b> List of quantitative restrictions that are currently in force. <input type="checkbox"/> <b>Section 2:</b> Cross-reference to other WTO notifications with information on quantitative restrictions that are currently in force and additional information.

\* In English only.

**G. Comments of a general nature, including a description of the elimination of restrictions notified under D.2.2 and the date they ceased to be in force.**

The EU is notifying an urgency measure of temporary application in relation to the COVID-19 pandemic. The export authorisation requirement for COVID-19 vaccines applies to exports of vaccines produced by companies with whom the EU has Advance Purchase Agreements. It has a duration of six weeks but could be extended until 31 March 2021. Based on the principle of international solidarity, exports to several destinations are exempted from the measure, such as, in particular, exports related to COVAX, in the context of a humanitarian emergency response as well as to EFTA, the Western Balkans and the EU neighbourhood.

**Section 1: List of quantitative restrictions that are currently in force**

QR No.	General description of the restriction	Type of restriction	Tariff line code (s) affected, based on HS (2017)	Detailed Product Description	WTO Justification and Ground for Restriction, e.g. Other International Commitments	National legal basis and entry into force	Administration, modification of previously notified measures, and other comments
	1	2	3	4	5	6	7
1	Export authorisation for COVID-19 vaccines	NAL-X	ex 3002 20	Vaccines against SARS-related coronaviruses (SARS-CoV species), irrespective of their packaging, and active substances including master and working cell banks used for the manufacture of such vaccines	Protection of human life or health, <i>inter alia</i>	<p>Commission Implementing Regulation (EU) 2021/111 of 29 January 2021 making the exportation of certain products subject to the production of an export authorization; Official Journal L 31I, 30.1.2021</p> <p><a href="https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32021R0111&amp;from=EN">https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32021R0111&amp;from=EN</a></p> <p>Application period: from 30.01.2021 for six weeks; could be extended until 31.03.2021</p>	<p>Administration: Competent authorities in EU Member States</p> <p>Exemptions include (see Article 1.5 of the regulation):</p> <ul style="list-style-type: none"> <li>- exports in the context of humanitarian aid;</li> <li>- exports to low and middle income countries in the COVAX Advance Market Commitment (AMC) list (<a href="https://www.gavi.org/news/media-room/92-low-middle-income-economies-eligible-access-covid-19-vaccines-gavi-covax-amc">https://www.gavi.org/news/media-room/92-low-middle-income-economies-eligible-access-covid-19-vaccines-gavi-covax-amc</a>);</li> </ul> <p>exports of goods purchased and/or delivered through COVAX, UNICEF and PAHO with destination to any other COVAX participating country;</p>

QR No.	General description of the restriction	Type of restriction	Tariff line code (s) affected, based on HS (2017)	Detailed Product Description	WTO Justification and Ground for Restriction, e.g. Other International Commitments	National legal basis and entry into force	Administration, modification of previously notified measures, and other comments
	1	2	3	4	5	6	7
							<p>- Albania, Algeria, Andorra, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Egypt, Faeroe Islands, Georgia, Holy See, Iceland, Israel, Jordan, Kosovo<sup>1</sup>, Lebanon, Libya, Liechtenstein, Moldova, Montenegro, Morocco, Norway, North Macedonia, Palestine<sup>2</sup>, San Marino, Serbia, Switzerland, Syria, Tunisia, Ukraine;</p> <p>- EU overseas countries and territories</p>

<sup>1</sup> This designation is without prejudice to positions on status, and is in line with UNSCR 1244/1999 and the ICJ Opinion on the Kosovo declaration of independence.

<sup>2</sup> This designation shall not be construed as recognition of a State of Palestine and is without prejudice to the individual positions of the EU Member States on this issue.